Beyfortus

The FDA has approved the second monoclonal antibody for the prevention of RSV in neonates and infants, ...

JUNE 10, 2025

Sanofi said it would ship nirsevimab starting earlier to ensure broad availability well ahead of the 2025-2026 RSV ...

JUNE 9, 2025

RSV-associated hospitalization in infants fell sharply during the first virus season after the introduction of ...

JUNE 5, 2025

Early real-world data show that a single injection of the monoclonal antibody nirsevimab was 83% effective in ...

OCTOBER 11, 2024

A new AI tool may help identify newborns at the highest risk of developing serious RSV lower respiratory tract ...

MAY 21, 2024

Interim data from the CDC show that Beyfortus is highly effective in reducing infants’ risk for ...

MAY 15, 2024

The CDC announced 77,000 additional doses of nirsevimab-alip, a long-acting monoclonal antibody designed to protect ...

NOVEMBER 16, 2023

It's difficult to predict the severity of the next respiratory season, but we asked two experts to try. Here's what ...

AUGUST 29, 2023

There might be several obstacles to administering Beyfortus. Pediatricians are going to need help overcoming them.

AUGUST 8, 2023

The CDC recommended a new passive immunization starting this fall to help protect all infants younger than 8 months ...

AUGUST 4, 2023

The CDC’s Advisory Committee on Immunization Practices voted unanimously for universal use of nirsevimab ...

AUGUST 3, 2023